Nobel Prize Winner Professor Avram Hershko Named to Oramed Pharmaceuticals Scientific Advisory Board
10 July 2008 - 10:00PM
PR Newswire (US)
JERUSALEM, July 10 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com/), a
developer of oral delivery systems, announced today that Nobel
Prize Laureate Professor Avram Hershko has joined Oramed's
Scientific Advisory Board, enhancing the Company's talented and
experienced scientific team. Professor Hershko earned his MD and
PhD from the Hebrew University-Hadassah Medical School of Jerusalem
and did a post-doctoral fellowship with Gordon Tomkins at the
University of San Francisco. He joined the faculty of the Technion,
Israel Institute of Technology, and was appointed professor in
1980. He currently serves as Distinguished Professor in the Unit of
Biochemistry in the B. Rappaport Faculty of Medicine of the
Technion. His main research interests concern the mechanisms by
which cellular proteins are degraded, a formerly neglected field of
study. Through their research, Professor Hershko and his colleagues
proved that cellular proteins are degraded by a highly selective
proteolytic system. Professor Hershko was awarded the Nobel Prize
in Chemistry in 2004 jointly with his former PhD student Aaron
Ciechanover and their colleague Irwin Rose, for the discovery of
ubiquitin-mediated protein degradation. His many honors include the
Israel Prize for Biochemistry (1994), the Gardner Award (1999), the
Lasker Prize for Basic Medical Research (2000), the Wolf Prize for
Medicine (2001) and the Louisa Gross Horwitz Award (2001). He is a
member of the Israel Academy of Sciences (2000) and a Foreign
Associate of the US Academy of Sciences (2003). "Professor Hershko
is one of the world's most highly respected scientists and we are
honored that he is joining our Scientific Advisory Board," said
Oramed CEO Nadav Kidron. "His expertise is precisely in the field
in which our technology is used, and having him as part of our team
will help us expand our core technology platform to a wider array
of products." "It is a privilege to join Oramed's talented
scientific advisory team and I look forward to helping the Company
make a significant difference for millions of diabetics around the
world," said Professor Hershko. Professor Hershko is replacing
Itamar Raz, MD, who will be leaving the board due to time
constraints. About Oramed Pharmaceuticals Oramed Pharmaceuticals is
a technology pioneer in the field of oral delivery solutions for
drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule
currently in phase 2 clinical trials. Established in 2006, Oramed's
technology is based on over 25 years of research by top research
scientists at Jerusalem's Hadassah Medical Center. The Company's
corporate and R&D headquarters are based in Jerusalem. For more
information, please visit http://www.oramed.com/ Forward-looking
statements Some of the statements contained in this press release
are forward-looking statements which involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry
results, to be materially different from any future results,
performance or achievements expressed or implied by such forward
looking statements, including the risks and uncertainties related
to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg Cell:
+972-54-566-7713 Office +972-2-566-0001 Email: Media Contacts:
Ruder Finn Israel for Oramed Matthew Krieger Cell: +972-54-467-6950
Office: +972-2-589-2003 Email: DATASOURCE: Oramed Pharmaceuticals
Inc. CONTACT: Company and Investor Relation Contacts: Oramed
Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office
+972-2-566-0001, Email: ; Media Contacts:, Ruder Finn Israel for
Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office:
+972-2-589-2003, Email:
Copyright